Trial Profile
Single centre retrospective study to evaluate the risk of thrombotic events associated with lenalidomide based therapy in newly diagnosed and relapsed refractory multiple myeloma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.